Bioverativ

This page shows the latest Bioverativ news and features for those working in and with pharma, biotech and healthcare.

Sanofi gets EU OK for Ablynx flagship drug Cablivi

of Bioverativ earlier this year which added two marketed haemophilia drugs as well as a pipeline of blood disorder products including genome editing drugs and gene therapies.

Latest news

Dupixent bounce-back helps stem diabetes declines at Sanofi

A bright point was the rare blood disorder business bolted on with the $11.6bn acquisition of Bioverativ, up 15.5% on a pro forma basis to 257m, and Sanofi is
Sanofi poaches Peugeot's finance head

However it has made some promising new acquisitions this year, including haemophilia and blood disorder specialists Bioverativ, which it bought for $11.6bn.
Evotec says Sanofi deal makes it anti-infectives powerhouse

revamp of its pipeline following the acquisitions of Ablynx and Bioverativ.
BioMarin ups the ante for pivotal haemophilia gene therapy trial

In the chase are Spark Therapeutics’SPK-8011, Pfizer/Sangamo Biosciences’SB-525 and Shire’s SHP654 - all in phase I/II testing - with uniQure and Sanofi’s Bioverativ unit also
Sanofi warns of difficult few months as diabetes sales slump

said that the last few months have included the pipeline-building acquisitions of Bioverativ and Ablynx and the sale of its Zentiva generics business to a private equity group. ... Furthermore, with the consolidation of Bioverativ and the acquisition of

More from news
Approximately 3 fully matching, plus 13 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

Biogen's spin-out, Bioverativ, had not even got past its first anniversary as a Nasdaq-listed company before being snapped up by Sanofi for $11.6bn (although this is not ... Paying $105 per share in cash (64% premium over Bioverativ’s closing price on

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Industry appointments

Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... The firm has managed to poach Bioverativ’s senior executive Rogerio Vivaldi (pictured
Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

the chief executive officer and president of Syntonix Pharmaceuticals - a wholly owned subsidiary of Biogen, now Bioverativ - and vice president of global operations.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Senior Account Manager- Central Oxford and Abingdon: Negotiable

New Business Director - PR: Competitive Salary and benefits

Production Manager – Healthcare Communications: DOE

Senior Medical Writer: Competitive Salary

Senior Medical Writer (Remote Working): Competitive Salary Offered

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Consumer Health Account Director: Circa £60, 000 Gym and More

Senior Account Manager: Negotiable

Senior Account Director development role to Business Director, H...: Excellent package

Medical Writers: Competitive Salary and Benefits

Senior Account Executive, London, Medical Communications: Excellent package

Medical/ Scientific Director: Salary TBC

Account Director: Excellent benefits

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Scientific Director / Editorial Team Leader: Great salary and benefits

Project / Account Manager (Medical Education): Salary TBC

Events Manager – Med Comms – Surrey: Salary TBC

Associate Director: £75, 000-90, 000

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Associate Editorial Director – Med Comms – London: Salary TBC

Account Director: £48, 000 - £60, 000

Subscribe to our email news alerts

PMHub

Add my company

Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Quality in Care Diabetes 2018: the best in innovative diabetes care: Awards highlight new evidence-based approaches to improving care...